12/12
05:52 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/12
05:52 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/11
07:55 am
ovid
Rating for OVID
Medium
Report
Rating for OVID
12/11
07:55 am
ovid
Rating for OVID
Medium
Report
Rating for OVID
12/11
06:03 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
12/11
06:03 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
12/11
05:14 am
ovid
Ovid Therapeutics initiated with a Buy at Roth Capital
Medium
Report
Ovid Therapeutics initiated with a Buy at Roth Capital
12/11
05:14 am
ovid
Ovid Therapeutics initiated with a Buy at Roth Capital
Medium
Report
Ovid Therapeutics initiated with a Buy at Roth Capital
11/24
07:19 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/17
08:06 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
11/17
07:25 am
ovid
Rating for OVID
Low
Report
Rating for OVID
11/17
06:19 am
ovid
Ovid Therapeutics initiated with an Outperform at Leerink
Low
Report
Ovid Therapeutics initiated with an Outperform at Leerink
10/10
12:04 pm
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
10/10
12:04 pm
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
10/9
08:44 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $7.00 price target on the stock.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $7.00 price target on the stock.
10/8
05:52 pm
ovid
Ovid Therapeutics initiated with an Outperform at Oppenheimer
High
Report
Ovid Therapeutics initiated with an Outperform at Oppenheimer
10/8
05:52 pm
ovid
Ovid Therapeutics initiated with an Outperform at Oppenheimer
High
Report
Ovid Therapeutics initiated with an Outperform at Oppenheimer